Benefit risk assessment and update on the use of docetaxel in the management of breast cancer

References

• SiegelRNaishadhamDJemalACancer statistics, 2013CA Cancer J Clin2013631113023335087
   PubMed Web of Science ®Google Scholar
• KessonEMAllardiceGMGeorgeWDBurnsWDMorrisonDSEffects of multidisciplinary team working on breast cancer survival: retrospective, comparative, interventional cohort study of 13 722 womenBMJ2012344e271822539013
   PubMed Web of Science ®Google Scholar
• PerouCMSorlieTEisenMBMolecular portraits of human breast tumoursNature200040674775210963602
   PubMed Web of Science ®Google Scholar
• KellyCMBernardPSKrishnamurthySAgreement in risk prediction between the 21-gene recurrence score assay (Oncotype DX(®)) and the PAM50 breast cancer intrinsic Classifier™ in early-stage estrogen receptor-positive breast cancerOncologist20121749249822418568
   PubMed Web of Science ®Google Scholar
• GelmonKDentRMackeyJRLaingKMcLeodDVermaSTargeting triple-negative breast cancer: optimising therapeutic outcomesAnn Oncol2012232223223422517820
   PubMed Web of Science ®Google Scholar
• LehmannBDBauerJAChenXIdentification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapiesJ Clin Invest20111212750276721633166
   PubMed Web of Science ®Google Scholar
• NortonLA Gompertzian model of human breast cancer growthCancer Res198848706770713191483
   PubMed Web of Science ®Google Scholar
• BonadonnaGBrusamolinoEValagussaPCombination chemotherapy as an adjuvant treatment in operable breast cancerN Engl J Med19762944054101246307
   PubMed Web of Science ®Google Scholar
• PetoRDaviesCGodwinJEarly Breast Cancer Trialists’ Collaborative Group (EBCTCG)Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trialsLancet201237943244422152853
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trialsLancet20053651687171715894097
   PubMed Web of Science ®Google Scholar
• PaikSShakSTangGA multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancerN Engl J Med2004351272817282615591335
   PubMed Web of Science ®Google Scholar
• ParkerJSMullinsMCheangMCUSupervised risk predictor of breast cancer based on intrinsic subtypesJ Clin Oncol20092781160116719204204
   PubMed Web of Science ®Google Scholar
• KellyCMHortobagyiGNAdjuvant chemotherapy in early-stage breast cancer: what, when, and for whom?Surg Oncol Clin N Am201019364966820620933
   PubMed Web of Science ®Google Scholar
• GuarneriVContePMetastatic breast cancer: therapeutic options according to molecular subtypes and prior adjuvant therapyOncologist200971464565619608638
   PubMed Web of Science ®Google Scholar
• WaniMCTaylorHLWallMECoggonPMcPhailATPlant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifoliaJ Am Chem Soc1971939232523275553076
   PubMed Web of Science ®Google Scholar
• ExtraJMRousseauFBrunoRClavelMLeBailNMartyMPhase I and pharmacokinetic study of Taxotere (RP 56976; NSC 628503) given as a short intravenous infusionCancer Res1993535103710428094996
   PubMed Web of Science ®Google Scholar
• Guéritte-VoegeleinFGuénardDLavelleFLe GoffMTMangatalLPotierPRelationships between the structure of taxol analogues and their antimitotic activityJ Med Chem1991349929981672159
   PubMed Web of Science ®Google Scholar
• BisseryMCNohynekGSanderinkGJLavelleFDocetaxel (Taxotere): a review of preclinical and clinical experience. Part I: Preclinical experienceAnticancer Drugs199563393355363368
   Web of Science ®Google Scholar
• ManfrediJJHorwitzSBTaxol: an antimitotic agent with a new mechanism of actionPharmacol Ther1984251831256149569
   PubMed Web of Science ®Google Scholar
• RingelIHorwitzSBStudies with RP 56976 (taxotere): a semisynthetic analogue of taxolJ Natl Cancer Inst1991832882911671606
   PubMed Web of Science ®Google Scholar
• CortesJEPazdurRDocetaxelJ Clin Oncol199513264326557595719
   PubMed Web of Science ®Google Scholar
• ValeroVHolmesFAWaltersRSPhase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancerJ Clin Oncol19951312288628948523051
   PubMed Web of Science ®Google Scholar
• ChanSFriedrichsKNoelDProspective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancerJ Clin Oncol19991782341235410561296
   PubMed Web of Science ®Google Scholar
• NabholtzJ-MSennHJBezwodaWRProspective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapyJ Clin Oncol19991751413142410334526
   PubMed Web of Science ®Google Scholar
• O’ShaughnessyJMilesDVukeljaSSuperior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: Phase III trial resultsJ Clin Oncol200220122812282312065558
   PubMed Web of Science ®Google Scholar
• PacilioCMorabitoANuzzoFNCI-Naples Breast Cancer GroupIs epirubicin effective in first-line chemotherapy of metastatic breast cancer (MBC) after an epirubicin-containing adjuvant treatment? A single centre phase III trialBr J Cancer20069491233123616622454
   PubMed Web of Science ®Google Scholar
• SparanoJAMakhsonANSemiglazovVFPegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase III studyJ Clin Oncol200927274522452919687336
   PubMed Web of Science ®Google Scholar
• FergusonTWilckenNVaggRTaxanes for adjuvant treatment of early breast cancerCochrane Database Syst Rev2007174CD00442117943815
   PubMed Web of Science ®Google Scholar
• MartinMPienkowskiTMackeyJAdjuvant docetaxel for node-positive breast cancerN Engl J Med2005352222302231315930421
   PubMed Web of Science ®Google Scholar
• FrancisPCrownJDi LeoAAdjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02–98 randomized trialJ Natl Cancer Inst2008100212113318182617
   PubMedGoogle Scholar
• GoldsteinLJO’NeillASparanoJAConcurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197J Clin Oncol2008264092409918678836
   PubMed Web of Science ®Google Scholar
• JoensuuHKellokumpu-LehtinenP-LBonoPAdjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancerN Engl J Med2006354880982016495393
   PubMed Web of Science ®Google Scholar
• CoudertBAsselainBCamponeMExtended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trialOncologist201217790090922610153
   PubMed Web of Science ®Google Scholar
• BiancoADMAManzioneLBoniCTaxit216 Study GroupSequential epirubicin-cocetaxel-CMF as adjuvant therapy of early breast cancer: results of the Taxit216 multicenter phase III trial [abstract]J Clin Oncol20062418SLBS520
   Google Scholar
• JonesSESavinMAHolmesFAPhase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancerJ Clin Oncol200624345381538717135639
   PubMed Web of Science ®Google Scholar
• EllisPBarrett-LeePJohnsonLSequential docetaxel as adjuvant chemotherapy for early breast cancer (TACT): an open-label, phase III, randomised controlled trialLancet200937396761681169219447249
   PubMed Web of Science ®Google Scholar
• MartinMSeguiMAAntónAAdjuvant docetaxel for high-risk, node-negative breast cancerN Engl J Med2012363232200221021121833
   PubMed Web of Science ®Google Scholar
• BearHDAndersonSSmithRESequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer:National Surgical Adjuvant Breast and Bowel Project Protocol B-27J Clin Oncol200624132019202716606972
   PubMed Web of Science ®Google Scholar
• SparanoJAWangMMartinoSWeekly paclitaxel in the adjuvant treatment of breast cancerN Engl J Med2008358161663167118420499
   PubMed Web of Science ®Google Scholar
• SmithTJKhatcheressianJLymanGH2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guidelineJ Clin Oncol200624193187320516682719
   PubMed Web of Science ®Google Scholar
• CarverJRShapiroCLNgAAmerican Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effectsJ Clin Oncol200725253991400817577017
   PubMed Web of Science ®Google Scholar
• BaselgaJCortesJKimSBPertuzumab plus trastuzumab plus docetaxel for metastatic breast cancerN Engl J Med2012366210911922149875
   PubMed Web of Science ®Google Scholar
• FumoleauPChevallierBKerbratPA multicentre phase II study of the efficacy and safety of docetaxel as first-line treatment of advanced breast cancer: report of the Clinical Screening Group of the EORTCAnn Oncol1996721651718777173
   PubMed Web of Science ®Google Scholar
• SlamonDEiermannWRobertNAdjuvant trastuzumab in HER2-positive breast cancerN Engl J Med20113651273128321991949
   PubMed Web of Science ®Google Scholar